Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active) Clinical Trial
Official title:
The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis
Interventional phase 3 study aiming to unravel the value of pulse steroids in achieving remission or low disease activity in refractory active JIA
First group will receive 2 consecutive days intravenous pulse of 125 mg methylprednisolone. Second group will not receive additional drugs. Assessment was done at baseline and every month for 3 months for both groups using Juvenile Arthritis Disease Activity Score (JADAS) and the American College of Rheumatology Pediatric 30, 50, and 70 response criteria (ACR Pedi. 30, 50, 70). ;